Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 Revaccination in Older Adults Previously Vaccinated With Arexvy or Abrysvo
NCT07117487Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV), sponsored by Moderna Inc. Started Aug 2025; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07117487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117487.